X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Merck Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs MERCK LTD - Comparison Results

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA MERCK LTD NATCO PHARMA/
MERCK LTD
 
P/E (TTM) x 24.3 33.3 72.9% View Chart
P/BV x 18.4 3.7 493.1% View Chart
Dividend Yield % 0.6 0.8 82.0%  

Financials

 NATCO PHARMA   MERCK LTD
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
MERCK LTD
Dec-16
NATCO PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs8771,060 82.7%   
Low Rs424623 68.0%   
Sales per share (Unadj.) Rs223.4632.4 35.3%  
Earnings per share (Unadj.) Rs31.145.7 68.0%  
Cash flow per share (Unadj.) Rs40.362.3 64.6%  
Dividends per share (Unadj.) Rs5.0011.00 45.5%  
Dividend yield (eoy) %0.81.3 58.8%  
Book value per share (Unadj.) Rs219.5388.8 56.5%  
Shares outstanding (eoy) m33.0716.60 199.2%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.91.3 218.7%   
Avg P/E ratio x20.918.4 113.7%  
P/CF ratio (eoy) x16.113.5 119.6%  
Price / Book Value ratio x3.02.2 136.9%  
Dividend payout %16.124.1 66.9%   
Avg Mkt Cap Rs m21,50413,969 153.9%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m1,1281,487 75.9%   
Avg. sales/employee Rs ThNM6,631.9-  
Avg. wages/employee Rs ThNM939.2-  
Avg. net profit/employee Rs ThNM479.4-  
INCOME DATA
Net Sales Rs m7,38910,498 70.4%  
Other income Rs m167242 68.9%   
Total revenues Rs m7,55610,741 70.3%   
Gross profit Rs m1,7931,135 158.0%  
Depreciation Rs m304276 110.5%   
Interest Rs m3660-   
Profit before tax Rs m1,2901,102 117.0%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m309343 89.9%   
Profit after tax Rs m1,027759 135.4%  
Gross profit margin %24.310.8 224.4%  
Effective tax rate %23.931.1 76.8%   
Net profit margin %13.97.2 192.4%  
BALANCE SHEET DATA
Current assets Rs m3,6816,410 57.4%   
Current liabilities Rs m3,1238,828 35.4%   
Net working cap to sales %7.6-23.0 -32.8%  
Current ratio x1.20.7 162.4%  
Inventory Days Days8958 155.1%  
Debtors Days Days5938 152.9%  
Net fixed assets Rs m7,6851,406 546.4%   
Share capital Rs m331166 199.2%   
"Free" reserves Rs m6,6706,286 106.1%   
Net worth Rs m7,2596,455 112.5%   
Long term debt Rs m9550-   
Total assets Rs m11,9578,828 135.4%  
Interest coverage x4.5NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.2 52.0%   
Return on assets %11.78.6 135.6%  
Return on equity %14.211.8 120.4%  
Return on capital %20.717.1 121.4%  
Exports to sales %39.48.3 475.2%   
Imports to sales %5.721.0 27.1%   
Exports (fob) Rs m2,908869 334.5%   
Imports (cif) Rs m4212,209 19.1%   
Fx inflow Rs m3,445959 359.3%   
Fx outflow Rs m7032,612 26.9%   
Net fx Rs m2,743-1,653 -165.9%   
CASH FLOW
From Operations Rs m1,4401,070 134.6%  
From Investments Rs m-1,089-750 145.3%  
From Financial Activity Rs m-353-150 235.4%  
Net Cashflow Rs m-1171 -0.9%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 51.8 2.8%  
Indian inst/Mut Fund % 7.8 18.2 43.1%  
FIIs % 16.6 1.0 1,663.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 29.1 89.3%  
Shareholders   25,395 28,591 88.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Feb 19, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - TTK HEALTHCARE COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS